Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
How Platelet, Reticulocyte Fraction Levels Impact MPNs
Ann Hematol; ePub 2017 Feb 28; Strati, Bose, et al
Both immature platelet fraction (IPF) and the immature reticulocyte fraction (IRF) appear to have a clinical impact in people with myeloproliferative neoplasms, according to a prospective analysis involving 217 individuals with MPNs.
Participants had either essential thrombocythemia (ET; 15%), polycythemia vera (PV; 20%), or myelofibrosis (MF; 65%). Investigators measured IPF and IRF. Among the results:
- PV and MF patients experienced higher levels of IPF and IRF.
- Male gender, thrombocytopenia, and PV diagnosis played a role in high IPF in PV and ET patients.
- For MF patients, the key factors in high IPF were elevated peripheral blasts, low platelet count, JAK2 V617F mutation, and previous therapy.
- Low hemoglobin, high reticulocyte count, and PV diagnosis played a role in high IRF in PV and ET patients.
- For MF patients, the key factors in high IRF were peripheral blasts and elevated reticulocytes.
Strati P, Bose P, Lyle L, et al. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: The immature platelet and reticulocyte fractions. [Published online ahead of print February 28, 2017]. Ann Hematol. doi:10.1007/s00277-017-2956-3.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al